Silvia Calatroni

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

Serena Merante, Ester Orlandi, Paolo Bernasconi et al. · PubMed · 2005 · 106 citations

Hematological Malignancy, Chronic Myeloid Leukemia, Medicine +14

World Health Organization classification in combination with cytogenetic markers improves the prognostic stratification of patients with <i>de novo</i> primary myelodysplastic syndromes

Paolo Bernasconi, Catherine Klersy, Marina Boni et al. · British Journal of Haematology · 2007 · 95 citations

Cytogenetics, Genetics, Genetic Epidemiology +21

Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution

Paolo Bernasconi, Catherine Klersy, Marina Boni et al. · Leukemia · 2005 · 86 citations

Karyotype Imaging, Hematological Malignancy, Bone Marrow Failure +10

Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients

Paolo Bernasconi, Paola Maria Cavigliano, Marina Boni et al. · Leukemia · 2003 · 66 citations

Hematological Malignancy, Bone Marrow Failure, Cytogenetics +12

A sequence of immuno‐chemotherapy with Rituximab, mobilization of <i>in vivo</i> purged stem cells, high‐dose chemotherapy and autotransplant is an effective 
and non‐toxic treatment for advanced follicular 
and mantle cell lymphoma

Mario Lazzarino, Luca Arcaini, Paolo Bernasconi et al. · British Journal of Haematology · 2002 · 61 citations

Immunology, Pathology, Metronomic Chemotherapy +21